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The growth hormone binding protein (GHBP) was isolated from the liver of Nili-Ravi buffaloes (Bubalus 
bubalis), reverse transcriptase-polymerase chain reaction (RT-PCR) amplified and sequence 
characterized. RT-PCR analysis demonstrated high degree sequence identities (97.3 to 99.6%) of 
BbGHBP cDNA with Bos taurus, Ovis aries and Capra hircus. An expression plasmid was constructed 
for the production of BbGHBP in Escherichia coli BL21 (RIPL) CodonPlus under the control of T7lac 
promoter. On induction with isopropyl β-D thiogalactopyranoside, the BbGHBP was expressed at levels 
>30% of the total E. coli proteins. The target protein expressed as inclusion bodies was solubilized in 
denaturing solution and refolded by step/pulsatile dilution method using cysteine and cystine redox 
potential. Purification to near homogeniety (>98%) was achieved by ion-exchange chromatography with 
a recovery yield of 64%. Mass spectrometric analysis of the purified BbGHBP showed a single peak of 
30,756 Da. A radioprotein assay evaluated the binding affinity of recombinant BbGHBP with iodinated 
bovine growth hormone (bGH) which demonstrated active conformation of BbGHBP. These results 
demonstrate high expression and sequence characterization of BbGHBP in Nili-Ravi buffaloes and 
provide the basis for the assessment of BbGHBP in other breeds of buffalo.  
 






The growth hormone system is comprised of growth 
hormone (GH), growth hormone receptor (GHR) and 
growth hormone binding protein (GHBP) (Edmondson et 
al., 2003). GH, a 22 kDa polypeptide also known as 
somatotropin is produced by somatotroph cells of the 
anterior pituitary gland (Ayuk and Sheppard, 2006). It 
acts on various organs and systems to stimulate growth,   
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activities of the body (Leung and Ho, 2001). Liver is the 
major site for GH action as it contains transmembrane 
receptors for GH binding that ultimately stimulates 
production of insulin like growth factor (IGF), through 
which most of the GH actions are mediated. 
GHR, a transmembrane protein encoded by GHR 
gene, belongs to a family of cytokine receptors and is 
mainly expressed in the liver (Bazan, 1990). It is 
comprised of 634 amino acids, having extracellular, 
transmembrane and cytoplasmic domains. It has a signal 
peptide of 1 to 18 amino acids, an extracellular domain 
(240 amino acids) from 19 to 258 amino acids which 
corresponds to the serum GHBP (which helps in 
circulating the GH throughout the body), as GH binds to 
this domain (Yang et al., 2007).  
The GHBP is a transporter  protein  for  the  GH  and  is 




encoded by the same GHR gene, as the extracellular 
domain of GHR (Leung and Ho, 2001). GH binds with 
high affinity and specificity to the GHBP as it binds with 
its receptor (Edens and Talamantes, 1998). In most of 
the mammals such as humans, monkey’s serum GHBP is 
generated by the proteolytic cleavage of the extracellular 
domain of the GHR (Baumann et al., 1989) while in 
rodents it is produced by alternative splicing (Edens et 
al., 1994). The serum GHBP measurement might be a 
useful indicator for the hepatic GHR status, as liver is the 
major source for GHBP mRNA (Tiong and Herington, 
1991). It also prolongs the half-life of the GH through 
competition with the GHR in vivo (Amit et al., 2000). 
Moreover, it acts as a reservoir or buffer for the GH 
system (Edmondson et al., 2003). However, the 
importance of GHBP in the GH system is widely 
increasing for its therapeutic use; for example in case of 
gigantism or acromegaly in which GH is circulating in an 
excess amount, GHBP/GHR administration can reduce 
the circulating levels of GH in humans (Molitch et al., 
2006). GHBP can also be useful in the treatment of 
disorders associated with the GH deficiency (dwarfism or 
GH deficiency syndrome); when GH is administered in 
combination with GHBP, it increases the stability and 
efficiency of GH in vivo (Ayuk and Sheppard, 2006).  
Bubalus bubalis is widely present in South Asian 
countries including Pakistan, as it plays leading role in 
enhancing the economy of the country by producing milk, 
meat and draught power. It is reported that milk and meat 
production of livestock can be improved by exogenous 
administration of GH (Bauman, 1999). Since GHBP 
prolongs the half-life of GH, it is anticipated that GHBP 
can increase the activity of GH, hence enhancing the 
animal productivity such as milk and meat. GHR/GHBP of 
rabbit (Sakal et al., 2000), human (Postel-Vinay et al., 
1991) and mouse (Moffat et al., 1999) have been 
isolated, cloned and expressed. In contrast, the 
assessment of GHBP in buffaloes (B. bubalis) has not 
been fully demonstrated in spite of the fact that buffaloes 
are reared in many parts of the world. Accordingly, the 
present study was conducted on the liver of Nili-Ravi 
breed in Pakistan to describe in detail sequence 
characterization, expression profile and refolding of 
BbGHBP in biologically active conformation.  
 
 
MATERIALS AND METHODS 
 
Animals, sample collection, chemicals, kits, plasmids and 
bacterial strains  
 
Liver samples of three Nili-Ravi buffaloes (15 years of age, about 
300 to 450 kg in body weight) were freshly collected from a local 
abattoir (Lahore, Pakistan). The liver samples were sliced into 10 x 
20 mm pieces and stored at -80°C till further analysis. 
Chemicals/reagents used in this study were of the highest purity 
grade commercially available. GF-1 Gel DNA Recovery and GF-1 
Plasmid DNA extraction kits used for DNA extraction and plasmid 
minipreparation were acquired from Vivantis Technologies Sdn. 





for sequencing of the gene. The vectors used for cloning and 
expression of BbGHBP include pTZ57R/T (Fermentas Inc. USA) 
and pET22b(+) (Novagen EMD Biosciences, Germany). E. coli host 
strains used in this study were DH5α and BL21 (RIPL) CodonPlus 
(Stratagene, USA). Iodinated bovine GH (125I-bGH) used for 
biological activity assay was a kind gift from NETRIA, UK. 
 
 
RT-PCR amplification and sequence analysis 
 
The total RNA was isolated from B. bubalis liver tissue using 
standard guanidinium isothiocynate phenol chloroform extraction 
method (Sambrook and Russell, 2001) and its concentration (µg/ml) 
was determined at 260 nm. A set of primers [GHBP-F (5´-
GTACATATGGATCTCTGGCAGCTGCTG-3´) and GHBP-R (5´-
ATGCTCGAGATCTTCTTCACATGCAGATG-3´)], designed on the 
basis of published nucleotide sequences of Bovidae species 
GHR/GHBPs (Accession nos. AY608917, NM_176608 and 
NM_001009323), was used for reverse transcription-based PCR 
amplification of BbGHBP. Conditions used for PCR were: initial 
denaturation at 95°C for 2 min followed by 30 cycles of amplification 
(94°C for 45 s, 57°C for 45 s and 72°C for 1 min) and final 
extension at 72°C for 20 min. The amplified product was analyzed 
on 1% agarose gel, purified and T/A cloned in pTZ57R/T vector and 
subcloned between NdeI/XhoI sites of pET22b(+) vector. The 
recombinant plasmid (pET-BbGHBP) obtained was used to 
transform E. coli strains DH5α (cloning host) and subsequently BL-
21 (RIPL) CodonPlus for expression. The transformants were 
selected on LB-ampicillin plates, sequence and correct integration 
of BbGHBP in the recombinant plasmid was confirmed by 
sequence analysis on Beckman Coulter CEQ8000TM Genetic 
Analyzer.  
The nucleotide sequence was translated using EMBL-EBI 
European Bioinformatics Institute (www.ebi.ac.uk) tool and aligned 
with GHBPs of Bovidae species such as Indian B. bubalis, Bos 
taurus, Ovis aries and Capra hircus using a multiple sequence 
alignment program MUSCLE (www.phylogeny.fr). The tertiary 
structure was predicted by I-TASSER version 1.1 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER) and visualized on 





For expression analysis of BbGHBP, E. coli BL21 (RIPL) 
CodonPlus cells transformed with pET-BbGHBP were grown 
overnight in 10 ml LB medium containing 100 µg/ml ampicillin at 
37°C, 150 rpm in an orbital incubator shaker. One percent of this 
overnight culture was used to inoculate 200 ml fresh LB-ampicillin 
broth in 2-L baffled flask and grown under same conditions 
mentioned above.  
Protein expression was induced with 0.5 mM IPTG when the 
culture A600 reached 0.5 to 0.7. After 8 h of induction, cells were 
harvested by centrifugation (6,000 rpm, 20 min, 4°C), resuspended 
in lysis buffer [50 mM Tris-Cl (pH 8.5), 100 mM NaCl, 5 mM EDTA, 
1 mM phenylmethyl sulfonyl flouride (PMSF)] and subjected to 
sonication (30 pulses with an interval of 1 min). The soluble and 
insoluble protein fractions were collected by centrifugation at 9,000 
rpm, 4°C for 15 min and analyzed by 12% SDS-PAGE (Laemmli, 
1970). The inclusion bodies (IBs) containing BbGHBP were washed 
twice with washing buffer [50 mM Tris-Cl (pH 8.5), 5 mM EDTA, 
0.5% Triton-× 100] followed by washing with 50 mM Tris-Cl (pH 8.5) 
and then solubilized in solubilization buffer [50 mM Tris-Cl (pH 9.5), 
10 mM EDTA, 8 M urea, 4 mM dithiothreitol]. The solution was 
incubated at room temperature for an hour and centrifuged (20,000 






Refolding and purification 
 
The expressed BbGHBP, obtained in the form of IBs, was refolded 
by the removal of denaturant and step dilution. Briefly, 50 mg 
solubilized protein was added in the refolding buffer [50 mM Tris-Cl 
(pH 9.5), 1 mM EDTA, 1 mM PMSF, 50 mM glycine, 1 mM cystine 
and 5 mM cysteine] gradually with gentle stirring at 4°C. DTNB [5, 
5′-dithiobis (2-nitrobenzoic acid)] assay or Ellman’s test was 
performed to estimate the free thiols at different stages of refolding 
process (Ellman, 1959). After 24 h of air oxidation, the solution was 
centrifuged at 20,000 rpm for 30 min and the clear solution obtained 
was dialyzed overnight against 20 mM Tris-Cl (pH 8.3) and then 
purified on Resource-Q column (1.6 x 3.0 cm) by fast protein liquid 
chromatography (FPLC). Prior to purification, the column was 
equilibrated with 2 column volumes of the running buffer [20 mM 
Tris-Cl (pH 8.3)]. The bound protein was eluted with continuous 
NaCl gradient (0.1 to 1 M) at a flow rate of 1 ml/min and dialyzed 
against 20 mM Tris-Cl (pH 8.3) to remove salt traces.  
 
 
Mass spectrometry and protein quantification 
 
Mass spectrometric analysis of the refolded, purified BbGHBP was 
performed using MALDI-TOF/TOF mass spectrometer (Bruker 
Daltonics, Germany). BbGHBP (1 µg) after mixing with 3,5 
dimethoxy-4-hydroxycinnamic acid was deposited onto the 
stainless steel target plate of mass spectrometer and analyzed in 
linear positive mode taking bovine serum albumin (BSA) as 
standard.  
Protein concentration was determined either by Bradford (1976) 
assay or by absorbance measurements at 280 nm on a UV-visible 
spectrophotometer (UV-2450, SHIMADZU) taking the absorbency 




Radioprotein binding assay 
 
The biological activity of BbGHBP was studied by radio protein 
binding assay set for 4 h at 4°C in duplicates. Different 
concentrations (200, 400, 800 and 1000 μg) of BbGHBP were 
made in 20 mM Tris-Cl (pH 8.3) and 100 µl was added in the assay 
tubes. Iodinated bovine GH (125I-bGH) of 20,000 c.p.m./100 μl and 
100 µl assay buffer [20 mM Tris-Cl (pH 8.3), 0.01 M CaCl2, 0.1 % 
BSA] was added and incubated for 4 h at 4°C. Non-specific binding 
was calculated by adding assay buffer and iodinated bGH. 1 ml 
polyethylene glycol (25% w/v) was added to each assay tube and 
centrifuged at 6,000 rpm for 30 min. Supernatant was discarded, 
tubes were dried and counts were read on gamma counter 
(LB2111, BERTHOLD TECHNOLOGIES GmbH & Co. KG) as 
specific binding or total binding. The percentage specific binding 
was calculated by the formula [(total binding – nonspecific binding) / 
total counts added × 100] (Cadman and Wallis, 1981).  
 
 
RESULTS AND DISCUSSION 
 
RT-PCR amplification and sequence analysis 
 
Total RNA isolated from liver tissue of indigenous B. 
bubalis (Nili-Ravi) was RT-PCR amplified using gene-
specific primers to obtain 0.77 kb long BbGHBP cDNA. 
The amplicon was T/A cloned and sequenced using M13 
universal primers both in the forward and reverse 
directions to resolve discrepancies, if any. The nucleotide  




and deduced amino acid sequence was submitted to the 
NCBI GenBank Database and has accession no. 
JN558567.  
Comparison of the sequence with corresponding 
sequences from the selected Bovidae species (such as 
Indian B. bubalis, B. taurus, O. aries and C. hircus) 
showed high degree of sequence similarities that ranged 
between 97.3 and 99.6% (Figure 1). Here, of particular 
interest was the observation that GHBP of indigenous 
bubaline is more closely related to bovine (B. taurus) as 
compared to Indian bubaline GHBP. Three amino acid 
variations that is, Gly60→Glu60, Thr87→Ile87 and 
Arg127→Ser127 were noticed when the sequences of the 
two BbGHBPs were compared. With bovine, the 
BbGHBP of the indigenous bubaline showed just a single 
amino acid difference at position 251 where Ser251 has 
been replaced by Asn251 which is the only variation which 
is common in the two BbGHBPs. Although, the observed 
variations were apparently not present in the binding 
region of the GHBP (Allan et al., 1999; de Vos et al., 
1992), yet to see the impact of three additional amino 
acid variations on 3-dimensional conformation of Nili-Ravi 
BbGHBP, we built the 3D-model using I-TASSER 
program and visualized on VMD (Figure 2). As shown, 
the amino acids difference in the BbGHBP are in the 
turns/coil regions and none is in the binding subdomains 
1 and 2 (characterized by the presence of seven 
extended β-sheets in antiparallel fashion) suggesting that 
the binding properties of GHBPs are less likely to be 
influenced as a consequence of three additional 
variations reported in the case of Indian BbGHBP.  
 
 
Construction of expression plasmid 
 
Approximately 0.77 kb long cDNA of BbGHBP containing 
NdeI and XhoI overhangs was cloned in T7lac promoter-
based pET22b(+) vector between NdeI/XhoI sites to 
generate pET-BbGHBP expression plasmid (Figure 3). 
The recombinant plasmid was initially maintained in E. 
coli DH5α for vector propagation and then transformed 
into E. coli BL21 (RIPL) CodonPlus for expression 
studies. Prior to expression analysis, the correct/in-frame 
integration of insert in the expression plasmid was 
confirmed by restriction digestion and nucleotide 
sequencing (data not shown).  
Proteins from the induced E. coli cells harboring pET-
BbGHBP showed a prominent band at position 
corresponding to ~30 kDa within initial one hour of IPTG 
induction, when analyzed by SDS-PAGE. The expression 
levels increased rapidly reaching a maximum of ~30% of 
the total E. coli cellular proteins with 3 h of induction and 
remained constant thereafter. As expected, a band of 
similar size and intensity was absent in uninduced cells 
(Figure 4, Lane 1). After 8 h of induction, a gradual 
decrease in expression and cell mass was observed 
most probably due to cell lysis and depletion  of nutrients.  






Figure 1. Multiple sequence alignment of BbGHBP (accession no. JN558567) with selected members of Bovidae 
family viz., Indian B. bubalis [bubaline, BbGHBP(Ind.), accession no. AY608917], B. taurus [bovine, BtGHBP, 
accession no. NM_176608], O. aries [ovine, OaGHBP, accession no. NM_001009323], C. hircus [caprine, 






Figure 2. Three-dimension model of Nili-Ravi buffalo BbGHBP 
built using I-TASSER program.  
 
 
Figure 3. Construction of pET-BbGHBP expression 
plasmid. ~0.77 kb long BbGHBP cDNA was inserted 
between NdeI/XhoI sites of pET22b (+) through 




In all subsequent experiments, induction was therefore 







Figure 4. Analysis of induced E. coli cell proteins by 12% 
SDS-PAGE. Lanes: M, protein marker; 1 to 4, uninduced 
(control), total cell proteins, soluble proteins, and insoluble 




Further, the analysis of soluble and insoluble protein 
fractions on SDS-gel revealed that BbGHBP expression 
is in the form IBs, which constitute over 70% of the total 
insoluble protein fraction (Figure 4, Lane 4). In prior 
studies, rat (Baumbach et al., 1989), monkey (Martini et 
al., 1997) and mouse (Moffat et al., 1999) GHR/GHBP 
had been expressed in bioactive form using the 
mammalian expression systems. In the present study, 
however, E. coli based expression system resulted in 
high-level expression of BbGHBP in the form of IBs as 
the system lacks refolding machinery. IBs thus obtained 
were therefore recovered, solubilized and refolded to 
obtain biologically active recombinant protein.  
 
 
Refolding and purification 
 
The IBs containing BbGHBP were recovered from the 
lysed E. coli cells by low speed centrifugation and 
washed twice with Triton-X 100. The purity of BbGHBP 
attained at this stage was over 75% as judged by 
densitometric analysis of 12% SDS-gel (Figure 4, Lane 
4). Following washing, the native and non-native intra- 
and inter-chain interactions of IB proteins were disrupted 
completely using high concentration of urea (8 M) and 
dithiothreitol. While, for the solubilization of extracellular 
domain of rabbit GHR, lower molar concentration of urea 
(4.5 M) was used (Sakal et al., 2000). The refolding was 
then initiated through pulsatile addition of solubilized 
protein at a rate of 0.1 ml/min in a refolding sink 
containing renaturation solution, which was 10 times the 
volume   of  solubilized  protein,  followed  by  removal  of 





Table 1. DTNB assay for the estimation of free thiols. A412 
measurements showing the free thiol groups present in the 
refolding sink before and after the addition of solubilized IB proteins 
at different time intervals.  
 
Sample A 412 
  





Before the addition of solubilized 
protein 
0.21 
1 h post-addition 0.37 
5 h post-addition 0.21 
12 h post-addition 0.14 
18 h post-addition 0.09 




denaturant, which is, urea by dialysis.  
Too high concentrations of protein during the refolding 
process often lead to the formation of aggregated species 
thus resulting in poor refolding yields (Li et al., 2004). In 
the present study, the final concentration of solubilized 
protein in the refolding sink was maintained at 0.1 mg/ml 
to prevent the aggregate formation. Presence of glycine, 
an aggregation suppressor (Qoronfleh et al., 2007), in the 
refolding sink further assisted the prevention of misfolded 
or unfolded protein aggregates. On the other hand, 
oxidized and reduced cysteine provided appropriate 
redox potential for the formation of disulfide bonds. 
During the refolding process, the presence of free thiols 
in the refolding sink was monitored by DTNB assay (Fuh 
et al., 1990) and the results are indicated in Table 1. In 
the beginning, the concentration of free thiols was high as 
reflected by A412 measurements. But with the passage of 
time, a gradual decrease in free thiols has been 
demonstrated and after 24 h of air oxidation, the A412 
dropped down to 0.06 indicating an almost complete 
oxidation of cysteine residues, which was present at the 
beginning of the experiment in the reduced state.  
Following refolding step, dialysis was performed for 
buffer exchange and the dialysate was subjected to anion 
exchange-based Resource-Q column chromatography 
(Figure 5A). The bound protein could be eluted with 0 to 
0.8 M NaCl gradient. Similar strategy was employed for 
the purification of rabbit extracellular domain of GHR  
 (Sakal et al., 2000). The fraction numbers 128 to 146 
containing BbGHBP were pooled and dialyzed against 20 
mM Tris-Cl (pH 8.3) to remove salt traces. The 
percentage purity attained was >98%, whereas the 
recovery was ~64% (Table 2).  
 
 
Mass spectrometry and biological activity 
assessment 
 
The   identity   of    purified   and   refolded    protein   was  




Table 2. Summary of the percentage recovery of BbGHBP at different stages of purification. 
 




 Recovery (%) 
Inclusion bodies 50.0 75 100 
Refolding & dialysis 45.8 80 92 
FPLC 32.0 98 64 
 
a
 Protein concentration was determined by absorbance measurements at A280. 
b
 The percentage purity was 






Figure 5. A) Elution profile of BbGHBP fractionated on Resource-Q column. B) MALDI-TOF analysis of purified 






Figure 6. Assessment of biological activity by radioprotein binding 
assay. Binding of the tracer (125I-bGH, 20,000 c.p.m.) to different 
BbGHBP concentrations (200, 400, 600, 800 and 1000 μg/tube) is 




monitored by MALDI-TOF/TOF mass spectrometry, 
which showed a single peak of 30,756 Da (Figure 5B). 
Furthermore, the biological activity of BbGHBP was 
assessed by its ability to bind with iodinated 
125
I-bGH in a 
radioprotein binding assay. As shown in Figure 6, the 
non-specific binding was negligible, whereas the specific 
binding of BbGHBP with the 
125
I-bGH was over 50%. 
These results confirmed the biologically active confor-





The current study describes sequence and high-level 





first time. The findings would certainly be used as 
reference data for comparison in other breed of buffaloes 
in Pakistan as well as in other regions of the world. Also, 
the results would contribute towards developing 
procedures for large-scale production of BbGHBP for 
further studies where the use of GH in combination with 
GHBP would enhance the galactopoetic and 
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